CompletedPhase 1NCT03330899
Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil
Studying Avian influenza
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Butantan Institute
- Principal Investigator
- Esper Kallas, PhDUniversity of Sao Paulo
- Intervention
- H7N9 antigen + adjuvant IB160(biological)
- Enrollment
- 432 enrolled
- Eligibility
- 18-59 years · All sexes
- Timeline
- 2018 – 2020
Study locations (3)
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
- Centro de Pesquisas Clínicas do Instituto Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
- Centro de Pesquisa Clínica do Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - ICr/HCFMUSP, São Paulo, São Paulo, Brazil
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03330899 on ClinicalTrials.govOther trials for Avian influenza
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07496450A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsModernaTX, Inc.
- RECRUITINGPHASE3NCT07240558Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)University Health Network, Toronto
- ACTIVE NOT RECRUITINGPHASE4NCT07275060Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks ApartCanadian Immunization Research Network
- RECRUITINGPHASE1, PHASE2NCT06842173Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older AdultsButantan Institute
- ACTIVE NOT RECRUITINGPHASE1NCT07019883A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy AdultsNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNANCT06850298H5N1 Milk Detection StudyEmory University